← Leaderboards
Kaustubh Datta
Mayo Clinic Rochester
$4,907,721
Attributed
$4,907,721
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $347.8K · FY2010–24$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,907,721 · 3
By mechanism
R01$4,907,721 · 3
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Jinghua Hu$8,003,740
- Nicholas E Vlahakis$630,720
- Sujit Basu$9,062,631
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularReceptorMediatingCancer PatientComplexNeuropilin-2Effective TherapyMalignant Neoplasm Of ProstateTumorProstate Cancer CellRadiationCohortTherapeutic InterventionTissuesDeprivationCell PhysiologyAndrogensCellsMalignant NeoplasmsParacrineMouse ModelNeoplasm MetastasisResistanceApoptosis
Grant awards (15)
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer$337,378
R01 · FY2024 · CA · contact PI
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer$340,803
R01 · FY2023 · CA · contact PI
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer$340,803
R01 · FY2022 · CA · contact PI
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer$347,758
R01 · FY2021 · CA · contact PI
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer$347,758
R01 · FY2020 · CA · contact PI
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis$333,940
R01 · FY2019 · CA · contact PI
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis$344,269
R01 · FY2018 · CA · contact PI
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis$344,269
R01 · FY2017 · CA · contact PI
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis$344,269
R01 · FY2016 · CA · contact PI
Neuropilin-2 Axis in Docetaxel Resistance and Prostate Cancer Bone Metastasis$344,269
R01 · FY2015 · CA · contact PI
The role of VEGF-C in resisting stress in prostate cancer$289,926
R01 · FY2014 · CA · contact PI
The role of VEGF-C in resisting stress in prostate cancer$280,960
R01 · FY2013 · CA · contact PI
The role of VEGF-C in resisting stress in prostate cancer$298,893
R01 · FY2012 · CA · contact PI
The role of VEGF-C in resisting stress in prostate cancer$298,893
R01 · FY2011 · CA · contact PI
The role of VEGF-C in resisting stress in prostate cancer$313,533
R01 · FY2010 · CA · contact PI